As far as medical markets are concerned, peripheral artery disease is still the baby sister of cardiovascular disease, walking in its shadow and making use of its hand-me-downs. Yes, just like coronary disease, peripheral artery disease is a function of atherosclerosis and lumen narrowing and blockage, and they share the same cardiovascular risk factors, like smoking, diabetes, obesity, high blood pressure, and 65 and older patient population. But it's a different disease with its own anatomical and biomechanical challenges, and since it's also deadly, deserves its own therapies.
Percutaneous transluminal angioplasty (PTA), borrowed from coronary markets, still remains the dominant treatment according to "US Markets for Interventional Peripheral Vascular Disease Management Products and Technologies," (a report recently published by the Medtech Insight division of Elsevier), and is still sometimes accompanied by the off-label use of stents adapted from coronary and biliary applications. Progress is being made on the part of companies developing peripherally dedicated stents. WL Gore & Associates Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?